Skip to main content
. 2022 Jul 7;140(1):38–44. doi: 10.1182/blood.2021014840

Table 2.

Clinical features and type of CD19-directed immunotherapy received by the 53 patients with R/R B-ALL and used for clinicobiological correlations

Group n
Adult vs Pediatric
 Pediatric* 15
 Adult 38
CD19-directed immunotherapy
 Blinatumomab 16
 Kymriah 14
 ARI001 23
Clinical outcome
 Relapse 27
 No relapse 26

Adapted from Ortiz-Maldonado et al.22,23

*

Age < 18 years.

Academic local CD19 CAR phase 1/2 trial (completed).